DE60233433D1 - PHARMAZEUTISCHE ZUBEREITUNG enthaltend ein Catechin, Ascorbinsäure, Prolin und Lysin ZUR BEHANDLUNG VON NEOPLASTISCHEN KRANKHEITEN - Google Patents
PHARMAZEUTISCHE ZUBEREITUNG enthaltend ein Catechin, Ascorbinsäure, Prolin und Lysin ZUR BEHANDLUNG VON NEOPLASTISCHEN KRANKHEITENInfo
- Publication number
- DE60233433D1 DE60233433D1 DE60233433T DE60233433T DE60233433D1 DE 60233433 D1 DE60233433 D1 DE 60233433D1 DE 60233433 T DE60233433 T DE 60233433T DE 60233433 T DE60233433 T DE 60233433T DE 60233433 D1 DE60233433 D1 DE 60233433D1
- Authority
- DE
- Germany
- Prior art keywords
- proline
- lysine
- ascorbic acid
- catechin
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 title abstract 6
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 title abstract 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 title abstract 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 title abstract 3
- 239000004472 Lysine Substances 0.000 title abstract 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 title abstract 3
- 229960005070 ascorbic acid Drugs 0.000 title abstract 3
- 235000010323 ascorbic acid Nutrition 0.000 title abstract 3
- 239000011668 ascorbic acid Substances 0.000 title abstract 3
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 title abstract 3
- 235000005487 catechin Nutrition 0.000 title abstract 3
- 229950001002 cianidanol Drugs 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000001613 neoplastic effect Effects 0.000 title abstract 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 title 1
- 229960003646 lysine Drugs 0.000 title 1
- 235000018977 lysine Nutrition 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 229960002429 proline Drugs 0.000 title 1
- 235000013930 proline Nutrition 0.000 title 1
- -1 catechin compound Chemical class 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Inorganic Chemistry (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/041,427 US6939860B2 (en) | 2002-01-08 | 2002-01-08 | Composition and method for treatment of neoplastic diseases associated with elevated matrix metalloproteinase activities using catechin compounds |
| PCT/EP2002/001005 WO2003057211A1 (en) | 2002-01-08 | 2002-01-31 | Composition inhibiting matrix-metallproteinases for the treatmentof neoplastic diseases. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60233433D1 true DE60233433D1 (de) | 2009-10-01 |
Family
ID=21916454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60233433T Expired - Lifetime DE60233433D1 (de) | 2002-01-08 | 2002-01-31 | PHARMAZEUTISCHE ZUBEREITUNG enthaltend ein Catechin, Ascorbinsäure, Prolin und Lysin ZUR BEHANDLUNG VON NEOPLASTISCHEN KRANKHEITEN |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US6939860B2 (de) |
| EP (1) | EP1463498B1 (de) |
| JP (1) | JP4144800B2 (de) |
| KR (1) | KR20050005408A (de) |
| CN (1) | CN1612731A (de) |
| AT (1) | ATE439833T1 (de) |
| AU (2) | AU2002244690A1 (de) |
| BR (1) | BR0208052A (de) |
| CA (1) | CA2469162A1 (de) |
| CZ (1) | CZ2004853A3 (de) |
| DE (1) | DE60233433D1 (de) |
| EE (1) | EE200400031A (de) |
| ES (1) | ES2332126T3 (de) |
| HR (1) | HRP20040705A2 (de) |
| HU (1) | HUP0402421A3 (de) |
| IL (1) | IL162384A0 (de) |
| LT (1) | LT5215B (de) |
| LV (1) | LV13249B (de) |
| MX (1) | MXPA04006627A (de) |
| NO (1) | NO20033949L (de) |
| NZ (1) | NZ533353A (de) |
| PL (1) | PL371205A1 (de) |
| RU (1) | RU2284185C2 (de) |
| SI (1) | SI21871A (de) |
| SK (1) | SK2772004A3 (de) |
| TR (1) | TR200401669T1 (de) |
| UA (1) | UA78979C2 (de) |
| WO (1) | WO2003057211A1 (de) |
| ZA (1) | ZA200404915B (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8669282B2 (en) * | 2000-10-31 | 2014-03-11 | Hill's Pet Nutrition, Inc. | Companion animal compositions including lipoic acid and methods of use thereof |
| US6939860B2 (en) * | 2002-01-08 | 2005-09-06 | Matthias Rath | Composition and method for treatment of neoplastic diseases associated with elevated matrix metalloproteinase activities using catechin compounds |
| US20050079234A1 (en) * | 2003-08-27 | 2005-04-14 | Chiang Yang Chi | Compositions comprising herbs and method for immunomodulation |
| KR20050070385A (ko) * | 2003-12-30 | 2005-07-07 | (주)현덕비엔티 | 폴리페놀과, 아스코르빈산 또는 그 유도체를 함유하는항암치료 보조용 조성물 |
| WO2006053184A2 (en) * | 2004-11-10 | 2006-05-18 | The Trustees Of Columbia University In The City Of New York | Methods for treating or preventing a vascular disease |
| ES2246737B1 (es) * | 2005-06-09 | 2006-12-01 | Jose Juan Rodriguez Jerez | "composicion farmaceutica que comprende lisina y usos correspondientes". |
| WO2007075176A1 (en) * | 2005-12-29 | 2007-07-05 | Mitsui Norin Co., Ltd | Compositions and methods of sensitizing methicillin resistant staphylococcus aureus to oxacillin |
| US20070265211A1 (en) * | 2006-05-12 | 2007-11-15 | Matthias Rath | Novel composition and method effective in inhibiting the atherogenic process |
| US20100055205A1 (en) * | 2008-08-29 | 2010-03-04 | Kristina Mains | Functional consumable compositions for promoting skin health and methods for using the same |
| EP2179722A1 (de) * | 2008-10-24 | 2010-04-28 | Heinrich-Pette-Institut für experimentelle Virologie und Immunologie | Topische Formation zur Vorbeugung der sexuellen Übertragung von Virusinfektionen |
| CA2977492C (en) | 2008-11-04 | 2019-03-12 | Vymedic, Llc | Antiviral supplement formulations |
| CN102656133B (zh) * | 2009-10-16 | 2015-04-15 | 株式会社钟化 | 还原型辅酶q10的制造方法、稳定化方法以及含有还原型辅酶q10的组合物 |
| ES2647566T3 (es) * | 2011-01-31 | 2017-12-22 | Lucolas-M.D. Ltd. | Combinaciones de inhibidores de aromatasa y antioxidantes |
| KR101829330B1 (ko) * | 2011-04-13 | 2018-02-20 | (주)아모레퍼시픽 | 염증성 피부 노화 억제 물질 스크리닝 방법 |
| CN102526170B (zh) * | 2011-12-31 | 2015-04-29 | 许学志 | 抗结核杆菌的儿茶提取物组合物、其制备方法及含有它们的药物制剂和应用 |
| BE1023772B9 (fr) * | 2013-05-17 | 2017-08-02 | Valore | Composition a base d'un complexe de (+)-catechine et d'acide amine pour le traitement et la prevention du cancer |
| CN104096058A (zh) * | 2014-07-02 | 2014-10-15 | 胥玲 | 一种治疗扩张型心肌病的中药药丸 |
| BE1022579A9 (fr) * | 2014-11-10 | 2016-10-06 | Valore | Composition antimétastatique comprenant au moins un composé de type flavanol |
| WO2024003061A1 (en) * | 2022-06-30 | 2024-01-04 | Lo.Li. Pharma S.R.L. | Composition for the treatment of the human papillomavirus infection (hpv) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5962517A (en) * | 1997-01-31 | 1999-10-05 | Murad; Howard | Pharmaceutical compositions and methods for treating acne |
| US5817695A (en) * | 1997-12-24 | 1998-10-06 | Pellico; Michael A. | Nutritional product with high fat, low carbohydrate and amino acid imbalance |
| KR20020016833A (ko) | 1999-06-15 | 2002-03-06 | 뉴트리-로직스, 인크. | 발병 감소에 유용한 영양 제제, 관련 치료 방법 및 성분스크리닝 방법 |
| US6939860B2 (en) * | 2002-01-08 | 2005-09-06 | Matthias Rath | Composition and method for treatment of neoplastic diseases associated with elevated matrix metalloproteinase activities using catechin compounds |
| CA2473634C (en) * | 2002-02-25 | 2011-11-29 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases |
-
2002
- 2002-01-08 US US10/041,427 patent/US6939860B2/en not_active Expired - Fee Related
- 2002-01-31 CN CNA028269543A patent/CN1612731A/zh active Pending
- 2002-01-31 MX MXPA04006627A patent/MXPA04006627A/es active IP Right Grant
- 2002-01-31 CZ CZ2004853A patent/CZ2004853A3/cs unknown
- 2002-01-31 JP JP2003557569A patent/JP4144800B2/ja not_active Expired - Fee Related
- 2002-01-31 KR KR10-2004-7010603A patent/KR20050005408A/ko not_active Application Discontinuation
- 2002-01-31 CA CA002469162A patent/CA2469162A1/en not_active Abandoned
- 2002-01-31 IL IL16238402A patent/IL162384A0/xx not_active IP Right Cessation
- 2002-01-31 AT AT02712877T patent/ATE439833T1/de active
- 2002-01-31 SI SI200220038A patent/SI21871A/sl not_active IP Right Cessation
- 2002-01-31 HU HU0402421A patent/HUP0402421A3/hu unknown
- 2002-01-31 EE EEP200400031A patent/EE200400031A/xx unknown
- 2002-01-31 SK SK277-2004A patent/SK2772004A3/sk not_active Application Discontinuation
- 2002-01-31 AU AU2002244690A patent/AU2002244690A1/en not_active Abandoned
- 2002-01-31 DE DE60233433T patent/DE60233433D1/de not_active Expired - Lifetime
- 2002-01-31 TR TR2004/01669T patent/TR200401669T1/xx unknown
- 2002-01-31 PL PL02371205A patent/PL371205A1/xx unknown
- 2002-01-31 BR BR0208052-4A patent/BR0208052A/pt not_active IP Right Cessation
- 2002-01-31 WO PCT/EP2002/001005 patent/WO2003057211A1/en active IP Right Grant
- 2002-01-31 ES ES02712877T patent/ES2332126T3/es not_active Expired - Lifetime
- 2002-01-31 EP EP02712877A patent/EP1463498B1/de not_active Expired - Lifetime
- 2002-01-31 UA UA20040705480A patent/UA78979C2/uk unknown
- 2002-01-31 NZ NZ533353A patent/NZ533353A/en unknown
- 2002-01-31 RU RU2004124047/15A patent/RU2284185C2/ru not_active IP Right Cessation
-
2003
- 2003-09-05 NO NO20033949A patent/NO20033949L/no not_active Application Discontinuation
-
2004
- 2004-06-22 ZA ZA200404915A patent/ZA200404915B/en unknown
- 2004-08-03 HR HR20040705A patent/HRP20040705A2/hr not_active Application Discontinuation
- 2004-08-05 LT LT2004074A patent/LT5215B/lt unknown
- 2004-09-06 LV LVP-04-88A patent/LV13249B/en unknown
- 2004-09-15 US US10/942,723 patent/US20050032715A1/en not_active Abandoned
-
2005
- 2005-08-24 US US11/211,389 patent/US20050281794A1/en not_active Abandoned
-
2008
- 2008-07-16 AU AU2008203157A patent/AU2008203157A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE439833T1 (de) | Pharmazeutische zubereitung enthaltend ein catechin, ascorbinsäure, prolin und lysin zur behandlung von neoplastischen krankheiten | |
| ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| ATE411280T1 (de) | Phenoxyessigsäure-derivate zur behandlung von störungen der atemwege | |
| ATE364698T1 (de) | Neues, physiologisch aktives peptid und dessen verwendung | |
| DE60112766D1 (de) | Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen | |
| ATE415962T1 (de) | Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs | |
| BRPI0411503A (pt) | composto, composição farmacêutica, uso de um composto, método de tratar um ser humano que sofre de uma doença hiperproliferativa tal como cáncer, e, processo para a preparação de um composto | |
| DE60027209D1 (de) | Arzneimittel enthaltend hydroxyapatite zur behandlung von knochengewebserkrankungen | |
| ATE399758T1 (de) | Derivate von 1-phenylalkancarbonsäuren zur behandlung von neurodegenerativen krankheiten | |
| DE60035693D1 (de) | Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten | |
| ATE409028T1 (de) | Arzneien zur behandlung von nervenerkrankungen | |
| ATE192923T1 (de) | Verwendung von boswelliasäure zur behandlung von hirntumoren | |
| ATE499933T1 (de) | Verwendung von betain zur behandlung von claudicatio intermittens | |
| ATE225171T1 (de) | Aminosäurederivate zur behandlung von schlaganfall | |
| ATE432936T1 (de) | Imidazotriazin verbindungen zur behandlung von krebserkrankungen | |
| DE50100833D1 (de) | Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen | |
| ATE285773T1 (de) | Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten | |
| DE602005027228D1 (de) | Zusammensetzungen und verfahren zur behandlung von krankheiten, die durch infektion mit yersinia spp ausgelöst sind | |
| DE60224429D1 (de) | Pharmazeutische zusammensetzung zur verwendung bei der behandlung von malignen erkrankungen, umfassend eine kombination aus bisphosphonaten, einem cox-2 inhibitor und einem taxol | |
| DE60306503D1 (de) | Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion | |
| ATE194076T1 (de) | Verwendung von n,s-diacetylcystein-ethylester (dacee) zur herstellung eines medikaments zur behandlung viraler erkrankungen | |
| ATE421961T1 (de) | Piperidinderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzung zur behandlung von alzheimer-krankheit, die diese derivate enthält | |
| DE10394363D2 (de) | Neue Chelidonin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von pharmazeutischen Wirkstoffen | |
| ATE364399T1 (de) | Einen zns-penetrierenden nk-1- rezeptorantagonisten und ein angstlösendes oder antidepressives mittel enthaltende zusammensetzung zur behandlung von depression und angst | |
| DE50302825D1 (de) | 2-methylthiazolidin-2,4-dicarbonsaeure und deren salze zur behandlung von neurodegenerativen erkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |